Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

University Hospital Groningen, Groningen, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Groningen
Treatments:ChemotherapyHospital:University Hospital Groningen
Drugs:Journal:Link
Date:Jan 2005

Description:

Patients: This Phase II study involved 108 patients. The patients were divided into two groups. 56 patients were assigned to Group A. The median age of Group A was 59, and twelve were women. 42 patients had Stage IV NSCLC, and 14 had Stage IIIb. All patients had been given previous chemotherapy, and 26 had been given previous radiotherapy.

Treatment: The treatment for patients in Group A consisted of one chemotherapeutic drug: docetaxel.

Toxicity: One patient died from the toxicity of treatment. Grade 1-4 hematologic toxicities included: granulocytopenia and leucopenia. Grade 1-3 non-hematologic toxicities included: diarrhea and vulnerability to infections.

Results: The median survival for Group A was 7.4 months (32 weeks).

Support: The authors acknowledged Aventis for its support for this study. Aventis manufactures and/or markets docetaxel.

Correspondence: H. J. M. Groen, MD





Back